Bicocca Open Archive

Logo unimib boa
CIACCIO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.753
EU - Europa 2.938
AS - Asia 2.401
SA - Sud America 445
AF - Africa 69
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 8
Totale 11.626
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.615
SG - Singapore 913
IT - Italia 665
CN - Cina 656
DE - Germania 490
RU - Federazione Russa 446
SE - Svezia 361
HK - Hong Kong 356
BR - Brasile 353
IE - Irlanda 268
UA - Ucraina 182
VN - Vietnam 167
GB - Regno Unito 158
CA - Canada 107
IN - India 94
AT - Austria 60
FI - Finlandia 57
DK - Danimarca 56
FR - Francia 55
AR - Argentina 33
TR - Turchia 32
BD - Bangladesh 30
NL - Olanda 28
PL - Polonia 27
BE - Belgio 25
ZA - Sudafrica 25
KR - Corea 24
MX - Messico 23
ES - Italia 19
JP - Giappone 19
EC - Ecuador 18
ID - Indonesia 14
CO - Colombia 13
IQ - Iraq 13
VE - Venezuela 11
ET - Etiopia 10
EU - Europa 10
IR - Iran 10
DZ - Algeria 8
SA - Arabia Saudita 8
TW - Taiwan 8
CZ - Repubblica Ceca 7
MA - Marocco 7
JO - Giordania 6
MY - Malesia 6
AU - Australia 5
BG - Bulgaria 5
EG - Egitto 5
OM - Oman 5
UZ - Uzbekistan 5
CL - Cile 4
GA - Gabon 4
HU - Ungheria 4
KE - Kenya 4
LT - Lituania 4
MM - Myanmar 4
PE - Perù 4
PH - Filippine 4
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
IL - Israele 3
JM - Giamaica 3
MD - Moldavia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PY - Paraguay 3
TH - Thailandia 3
TN - Tunisia 3
AZ - Azerbaigian 2
BH - Bahrain 2
BO - Bolivia 2
KW - Kuwait 2
NP - Nepal 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SR - Suriname 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
KZ - Kazakistan 1
LB - Libano 1
LI - Liechtenstein 1
ME - Montenegro 1
ML - Mali 1
MN - Mongolia 1
QA - Qatar 1
SC - Seychelles 1
SN - Senegal 1
TJ - Tagikistan 1
Totale 11.625
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.025
Singapore 577
Ashburn 487
Woodbridge 448
Hong Kong 356
Fairfield 350
Chandler 311
Houston 310
Frankfurt am Main 283
Dublin 260
Wilmington 219
Jacksonville 178
New York 173
Milan 170
Dearborn 154
Seattle 130
Cambridge 127
Beijing 112
Dallas 111
Princeton 104
Santa Clara 97
Los Angeles 90
Nanjing 66
Shanghai 60
Vienna 54
Altamura 53
Lawrence 47
Buffalo 45
Moscow 36
Rome 36
Hanoi 35
Ho Chi Minh City 34
São Paulo 33
Hefei 31
Lachine 31
Chicago 30
The Dalles 29
Council Bluffs 28
Dong Ket 26
Columbus 24
Guangzhou 24
Lissone 24
San Diego 23
Boston 21
Warsaw 21
London 20
Shenyang 20
Helsinki 19
Munich 18
Nanchang 18
Ottawa 18
Brussels 17
Fremont 16
Tianjin 16
Toronto 16
Andover 15
Phoenix 15
Pune 15
Tokyo 15
Changsha 14
Rio de Janeiro 14
Brooklyn 13
Jiaxing 13
Johannesburg 13
Manchester 13
Orem 13
Boardman 12
Denver 12
Jakarta 12
Jinan 12
Seoul 12
Zhengzhou 12
Atlanta 11
Haiphong 11
Bologna 10
Chennai 10
Hebei 10
Mexico City 10
Montreal 10
Nuremberg 10
Nürnberg 10
Poplar 10
Stockholm 10
Brasília 9
Hangzhou 9
Kunming 9
Mountain View 9
Ningbo 9
Sacramento 9
San Francisco 9
Da Nang 8
Dhaka 8
Edmonton 8
Bergamo 7
Elk Grove Village 7
Guayaquil 7
Montréal 7
Taizhou 7
Tampa 7
Valencia 7
Totale 7.534
Salva come PNG Salva come JPEG
Nome #
Impact of multidisciplinary team approach to liver tumors: 5-Years experience 466
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 432
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 393
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 333
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 278
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 276
Health related quality of life in chronic liver diseases 272
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 271
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 261
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 258
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 255
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 253
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 252
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 250
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 248
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 243
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 242
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 240
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 240
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 236
The impact of liver disease on the health-related quality of life 235
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 233
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 231
Health Related Quality of Life in the Major Liver Conditions 231
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 225
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 223
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 216
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 215
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 212
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 211
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 210
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 209
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 204
Difference in health related quality of life of chronic liver diseases and general population 201
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 200
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 200
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 193
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 186
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 185
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 181
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 181
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 176
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 170
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 166
Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? 162
Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: A systematic review and meta-analysis 157
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 150
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 149
Functional liver imaging score (FLIS) can predict adverse events in HCC patients 147
Sofosbuvir and ribavirinin in HCV-infected patients listed for liver transplantation: A cost-effectiveness analysis 142
Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis 142
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 142
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 107
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 102
Totale 11.993
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021624 0 0 0 0 0 76 72 98 96 99 76 107
2021/2022771 70 87 87 85 32 57 13 53 37 65 49 136
2022/20231.344 144 446 121 111 82 170 31 82 97 9 38 13
2023/2024856 30 33 22 68 86 262 158 37 61 12 8 79
2024/20252.021 108 210 146 83 172 91 134 71 234 347 148 277
2025/20262.448 630 217 396 558 619 28 0 0 0 0 0 0
Totale 11.993